# Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC

> **NCT05380271** · PHASE2 · UNKNOWN · sponsor: **Gang Wu** · enrollment: 60 (estimated)

## Conditions studied

- Carcinoma, Non-Small Cell Lung

## Interventions

- **DRUG:** sequential DEB-BACE and Arotinib and Tirelizumab
- **DRUG:** DEB-BACE alone

## Key facts

- **NCT ID:** NCT05380271
- **Lead sponsor:** Gang Wu
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-01
- **Primary completion:** 2022-12-01
- **Final completion:** 2025-12-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2022-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05380271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05380271, "Efficacy and Safety of DEB-BACE With Sequential Arotinib and Tirelizumab in the Treatment of Advanced NSCLC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05380271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*